Search

Michael A Fournel

from Raleigh, NC
Age ~74
Get Report
Also known as:
Diane C Fournel, Micheal A Fournel, Andrew M Fournel, Michael A Fournell, Mlchael Fournel, Mike Fournel
Phone and address:
1401 Silverling Way, Raleigh, NC 27613
(919) 847-3918
Related to:
Rena Ellis Norwood, 69Marjorie FournelTimothy Leonard, 63Susan Bowie, 62
Connected to:
Raymond A Fournelle, 83Lauren L Fournerat, 41Tracy L Fourness, 56Louis B Fournet, 76Stacey Fournet, 51Peter G Fournia, 81Adeline M Fournier, 37Al Fournier, 78Aleta B Fournier, 72Alexa Fournier

Michael Fournel Phones & Addresses

  • 1401 Silverling Way, Raleigh, NC 27613 (919) 847-3918 (919) 870-4670
  • 1041 Silverling Way, Raleigh, NC 27613
  • Beaufort, NC
  • Tahoe City, CA
  • San Rafael, CA
  • Madison, CT
  • Castro Valley, CA
  • Washington, DC
  • Chicago, IL
  • Berkeley, CA
  • Cary, NC
  • 1401 Silverling Way, Raleigh, NC 27613 (919) 870-4670

Work

Company: Inspiration biopharmaceuticals, inc Mar 2010 to Jun 2012 Position: Svp, r and d

Education

Degree: Associate degree or higher

Industries

Biotechnology

Resumes

Resumes

Michael Fournel Photo 1

Consultant

View page
Location:
Durham, NC
Industry:
Biotechnology
Work:
Inspiration Biopharmaceuticals, Inc Mar 2010 - Jun 2012
Svp, R and D
Independent Consultant Mar 2010 - Jun 2012
Consultant
Bayer Healthcare Sep 2002 - May 2007
Svp, Research and Development

Publications

Us Patents

Method For Evaluating Immunogenicity

View page
US Patent:
51477793, Sep 15, 1992
Filed:
Jun 1, 1988
Appl. No.:
7/202177
Inventors:
Pamela C. Esmon - Richmond CA
Michael A. Fournel - Castro Valley CA
Assignee:
Miles Inc. - Elkhart IN
International Classification:
C12Q 168
G01N 33543
US Classification:
435 6
Abstract:
A method for evaluating the potential immunogenicity of a protein derived from recombinant DNA technology. The method involves injecting an animal with the recombinant protein and then isolating antiserum from the animal. The antiserum is depleted of antibodies to a reference protein, i. e. , a plasma derived protein, by adsorbing the antiserum against the reference protein. The adsorbed antiserum is then blotted against the recombinant protein, to see if any antibodies were produced which recognize the recombinant protein, but did not recognize the plasma-derived protein during adsorption.

Method For Evaluating Immunogenicity

View page
US Patent:
51358743, Aug 4, 1992
Filed:
Mar 15, 1990
Appl. No.:
7/493659
Inventors:
Pamela C. Esmon - Richmond CA
Michael A. Fournel - Castro Valley CA
Assignee:
Miles Inc. - Elkhart IN
International Classification:
G01N 33543
US Classification:
436518
Abstract:
A method for evaluating the potential immunogenicity of a protein derived from recombinant DNA technology. The method involves injecting an animal with the recombinant protein and then isolating antiserum from the animal. The antiserum is depleted of antibodies to a reference protein, i. e. , a plasma derived protein, by adsorbing the antiserum against the reference protein. The adsorbed antiserum is then blotted against the recombinant protein, to see if any antibodies were produced which recognize the recombinant protein, but did not recognize the plasma-derived protein during adsorption.

Plasma Protein Fraction Substantially Free Of Acetate Ions

View page
US Patent:
43918018, Jul 5, 1983
Filed:
Oct 29, 1981
Appl. No.:
6/316201
Inventors:
Paul K. Ng - Hercules CA
Michael A. Fournel - Castro Valley CA
Assignee:
Cutter Laboratories, Inc. - Berkeley CA
International Classification:
A61K 3702
A61K 3704
US Classification:
424177
Abstract:
Stable plasma protein fractions (PPF) substantially free of vasodepressant amounts of acetate ions are disclosed. Solutions of the disclosed PPF are suitable for intravenous administration to patients without deleterious vasodepressor effects. Methods are also described for preparing the aforementioned PPF.
Control profile
Michael A Fournel from Raleigh, NC, age ~74 Get Report